University of Western Australia-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2019

  1. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia

    Atherosclerosis, Vol. 286, pp. 40-45

  2. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia

    Journal of the American College of Cardiology, Vol. 73, Núm. 9, pp. 1029-1039

2017

  1. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia

    Journal of Clinical Lipidology, Vol. 11, Núm. 1, pp. 260-271

  2. Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)

    Circulation, Vol. 135, Núm. 22, pp. 2133-2144

2016

  1. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

    Journal of the American College of Cardiology, Vol. 67, Núm. 11, pp. 1278-1285